Skip to content

Novel Serotonergic Psychedelic Agents as 5-HT2A Agonists for Treating Psychosis, Mental Illness, and CNS Disorders

Ram W. Sabnis

ACS Medicinal Chemistry Letters August 25, 2025 DOI: 10.1021/acsmedchemlett.5c00484 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Patent Peer reviewed
Topics Serotonin
Keywords Psychosis Mental illness Psychotherapist Receptor Mental health
Key points Argues that novel 5-HT2A agonist compounds can be used in pharmaceutical compositions to treat psychosis, mental illness, and CNS disorders.

Abstract

High Resolution Image Download MS PowerPoint Slide Provided herein are novel serotonergic psychedelic agents as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.

Explore topics